Related Experiment Video
Updated: May 23, 2025
04:29
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
28.1K
Selective Serotonin Reuptake Inhibitors May Increase Implant Failure
Michael S Block1, Don Mercante2
1Clinical Professor, Department of Oral and Maxillofacial Surgery, LSU School of Dentistry, Private Practice, Metairie, LA.
Summary
Patients taking selective serotonin reuptake inhibitors (SSRI) during dental implant surgery showed a significantly higher risk of implant failure within one year. This highlights a potential complication for patients on SSRI medication undergoing dental implant procedures.
Area of Science:
- Dental Implantology
- Pharmacology
- Clinical Research
Background:
- Selective serotonin reuptake inhibitors (SSRI) are commonly prescribed medications.
- Potential association between SSRI use and dental implant failure exists.
Purpose of the Study:
- To determine the association between SSRI exposure and dental implant failure.
- Quantify the risk of implant failure in patients using SSRIs.
Main Methods:
- Retrospective cohort study design.
- Included patients who received dental implants between December 2007 and February 2020.
- Analyzed SSRI exposure at implant placement as the predictor variable.
Main Results:
- SSRI exposure was associated with a 2.8-fold increased risk of implant failure at 1 year (Relative Risk = 2.8; 95% CI, 1.8-4.4).
- Implant failure rates were 18.6% for SSRI users versus 6.7% for non-users.
- Comorbidities like smoking, diabetes, osteoporosis, and frailty were also associated with implant failure.
Conclusions:
- SSRI use at the time of dental implant surgery may increase the risk of implant failure.
- Clinicians should consider SSRI use when assessing implant failure risk.
Related Concept Videos
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
271
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
271
01:23Antidepressant Drugs: MAOIs and Other Agents
175
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
175
01:30Electroconvulsive Therapy
22
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
22
01:21Drugs Affecting Neurotransmitter Release or Uptake
917
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
917
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
202
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
202